and N. A. Porter, Angew. Chem., Int. Ed., 2003, 42, 4370–4373; (d) M.
Wijtmans, D. A. Pratt, J. Brinkhorst, R. Serwa, L. Valgimigli, G. F.
Pedulli and N. A. Porter, J. Org. Chem., 2004, 69, 9215–9223; (e) H.-Y.
Kim, D. A. Pratt, J. R. Seal, M. Wijtmans and N. A. Porter, J. Med.
Chem., 2005, 48, 6787–6789; (f) T.-G. Nam, C. L. Rector, H.-Y. Kim,
A. F.-P. Sonnen, R. Meyer, W. M. Werner, J. Atkinson, J. Rintoul, D. A.
Pratt and N. A. Porter, J. Am. Chem. Soc., 2007, 129, 10211–10219;
(g) S. J. Nara, M. Jha, J. Brinkhorst, T. J. Zemanek and D. A. Pratt,
J. Org. Chem., 2008, 73, 9326–9333.
Acknowledgements
We are grateful for the support of the Natural Sciences and
Engineering Research Council of Canada, Ontario Ministry of
Innovation, and Queen’s University. D. A. P. also acknowledges
the support of the Canada Research Chairs program. This work
was also supported in part by grants from the NIH HL-17921, ES-
013125, GM-15431, and by grants from Merck-Frosst Canada &
Company and McNeil Consumer & Specialty Pharmaceuticals.
19 R. V. Panganamala, J. S. Miller, E. T. Gwebu, H. M. Sharma and D. G.
Cornwell, Prostaglandins, 1977, 14, 261–271; W. Seeger, U. Moser and
L. Roka, Arch. Pharmacol., 1988, 338, 74–81; P. Mantri and D. T.
Witiak, Curr. Med. Chem., 1994, 1, 328–355.
20 K. Yasumoto, A. Yamamoto and H. Mitsuda, Agric. Biol. Chem., 1970,
34, 1162–1168; V. E. Thody, D. R. Buckle and K. A. Foster, Biochem.
Soc. Trans., 1987, 15, 416–417; L. A. Dailey and P. Imming, Curr. Med.
Chem., 1999, 6, 389–398.
21 A. D. Becke, J. Chem. Phys., 1993, 98, 5648; C. Lee, W. Yang and R. G.
Parr, Phys. Rev. B, 1988, 37, 785.
22 G. A. DiLabio, D. A. Pratt, A. D. LoFaro and J. S. Wright, J. Phys.
Chem. A, 1999, 103, 1653.
23 G. A. DiLabio, D. A. Pratt and J. S. Wright, J. Org. Chem., 2000, 65,
2195.
References and notes
1 C. D. Funk, Science, 2001, 294, 1871–1875.
2 C. N. Serhan, N. Chiang and T. E. Van Dyke, Nat. Rev. Immunol., 2008,
8, 349–361.
3 See, e.g. (a) G. M. Chisholm and D. Steinburg, Free Radical Biol. Med.,
2000, 28, 1815–1826; (b) K. S. Montine, J. F. Quinn, J. Zhang, J. P.
Fessel, L. J. Roberts, J. D. Morrow and T. J. Montine, Chem. Phys.
Lipids, 2004, 128, 117–124; (c) L. J. Marnett, Carcinogenesis, 2000, 21,
361–370.
24 See, e.g. (a) M. Lucarini, G. F. Pedulli and M. Cipollone, J. Org. Chem.,
1994, 59, 5063; (b) D. D. M. Wayner, E. Lusztyk, K. U. Ingold and
P. Mulder, J. Org. Chem., 1996, 61, 6430; (c) M. Lucarini, P. Pedrielli,
G. F. Pedulli, S. Cabiddu and C. Fattuoni, J. Org. Chem., 1996, 61,
9259.
25 See, e.g. (a) T. C. P. Dinis, V. M. C. Madeira and L. M. Almeida,
Arch. Biochem. Biophys., 1994, 315, 161–169; (b) M. S. Nenseter, B.
Halvorsen, O. Rosvold, A. C. Rustan and C. A. Drevon, Arterioscler.
Thromb. Vasc. Biol., 1995, 15, 1338–1344; (c) T. Chou and P. Greenspan,
Biochim. Biophys. Acta, 2002, 1581, 57–63; (d) M. B. Ozsoy and A.
Pabuccuoglu, J. Clin. Biochem. Nutr., 2007, 41, 27–31.
26 Ingold and co-workers have shown that this interaction depresses the
rate, since the phenolic H-atom is no longer accessible for abstraction:
G. Litwinienko and K. U. Ingold, Acc. Chem. Res., 2007, 40, 222–230.
27 See, e.g. (a) G. W. Burton and K. U. Ingold, J. Am. Chem. Soc., 1981,
103, 6472; (b) G. W. Burton, T. Doba, E. J. Gabe, L. Hughes, F. L. Lee,
L. Prasad and K. U. Ingold, J. Am. Chem. Soc., 1985, 107, 7053; (c) R.
Amorati, G. F. Pedulli, L. Valgimigli, O. A. Attanasi, P. Filippone, C.
Fiorucci and R. Saladino, J. Chem. Soc., Perkin Trans. 2, 2001, 2142–
2146; (d) R. Amorati, F. Ferroni, G.F. Pedulli and L. Valgimigli, J. Org.
Chem., 2003, 68, 9654–9658.
4 See, e.g. J. Upston, L. Kritharides and R. Stocker, Prog. Lipid Res.,
2004, 32, 405–422 and literature cited therein.
5 C. A. Rouzer and L. J. Marnett, Chem. Rev., 2003, 103, 2239–2304.
6 A. R. Brash, J. Biol. Chem., 1999, 274, 23679–23682.
7 (a) P. J. Harvison, R. W. Egan, P. H. Gale, G. D. Christian, B. S. Hill and
S. D. Nelson, Chem. Biol. Interact., 1988, 64, 251; (b) M. Ouellet and
M. D. Percival, Arch. Biochem. Biophys., 2001, 387, 273; (c) F. Catella-
Lawson, M. P. Reilly, S. C. Kapoor, A. J. Cucchiara, S. DeMarco, B.
Tournier, S. N. Vyas and G. A. FitzGerald, N. Engl. J. Med., 2001, 345,
1809; (d) O. Boutaud, D. M. Aronoff, J. H. Richardson, L. J. Marnett
and J. A. Oates, Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 7130; (e) D. M.
Aronoff, J. A. Oates and O. Boutaud, Clin. Pharmacol. Ther., 2006, 79,
9.
8 See, e.g. (a) M. Q. Bromer and M. Black, Clin. Liver. Dis., 2003, 7, 351;
(b) L. P. James, P. R. Mayeux and J. A. Hinson, Drug Metab. Dispos.,
2003, 31, 1499; (c) W. M. Lee, Hepatology, 2004, 40, 6–9; (d) A. M.
Larson et al., Hepatology, 2005, 42, 1364–1372.
9 P. J. Harvison, A. J. Forte and S. D. Nelson, J. Med. Chem., 1986, 29,
1737–1743.
10 These are 5-LOX, 12S-LOX, 15-LOX-1, 12R-LOX, 15-LOX-2. A sixth
isoform exists, eLOX-3, which has been shown to isomerize 12R-
HPETE to a 11,12-epoxy-8-hydroxyeicosatrienoic acid; see: Z. Yu, C.
Schneider, W. E. Boeglin, L. J. Marnett and A. R. Brash, Proc. Natl.
Acad. Sci. U. S. A., 2003, 100, 9162–9167.
11 F. Jobard, C. Lefevre, A. Karaduman, C. Blanchet-Bardon, S. Emre, J.
Weissenbach, M. Ozguc, M. Lathrop, J. F. Prud’homme and J. Fischer,
Hum. Mol. Genet., 2002, 11, 107–13.
28 Y. Hsuanyu and H. B. Dunford, J. Biol. Chem., 1992, 267, 17649–
17657.
29 (a) D. M. Aronoff, O. Boutaud, L. J. Marnett and J. A. Oates,
J. Pharmacol. Exp. Ther., 2003, 304, 589–595; (b) C. M. Markey, A.
Alward, P. E. Weller and L. J. Marnett, J. Biol. Chem., 1987, 262, 6266.
30 The activity assay for COX is usually performed in presence of 500 mM
phenol to protect the enzyme from oxidative inactivation and to
enhance its catalytic activity. However, as phenol is a reducing co-
substrate, its presence in the reaction medium would confound the
results, and therefore it was omitted for these experiments.
31 L. M. Szewczuk, L. Forti, L. A. Stivala and T. M. Penning, J. Biol.
Chem., 2004, 279, 22727–22737.
12 X. Z. Ding, W. G. Tong and T. E. Adrian, Int. J. Cancer, 2001, 94,
630–636.
13 D. Harats, A. Shaish, J. George, M. Mulkins, H. Kurihara, H. Levkovitz
and E. Sigal, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2100–2105.
14 D. Pratico, V. Zhukareva, Y. Yao, K. Uryu, C. D. Funk, J. A. Lawson,
J. Q. Trojanowski and V. M. Lee, Am. J. Pathol., 2004, 164, 1655–62.
15 C. Kemal, P. Louis-Flamberg, R. Krupinski-Olsen and A. L. Shorter,
Biochemistry, 1987, 26, 7064–7072.
32 See, e.g. E. Marcinkiewicz, Z. Duniec and J. Robak, Biochem. Phar-
macol., 1985, 34, 148–149; Z. Duniec, J. Robak and R. Gryglewski,
Biochem. Pharmacol., 1983, 32, 2283–2286.
16 S. Whitman, M. Gezginci, B. N. Timmermann and T. R. Holman,
J. Med. Chem., 2002, 45, 2659–2661.
33 M. J. Nelson, Biochemistry, 1988, 27, 4273–4278.
34 S.P. Crouch, R. Kozlowski, K. J. Slater and J. Fletcher, J. Immunol.
Methods, 1993, 160, 81–88.
35 L. J. Marnett, P. H. Siedlik, R. C. Ochs, W. R. Pagels, M. Das, K. V.
Honn, R. H. Warnock, B. E. Tainer and T. E. Eling, Mol. Pharamcol.,
1984, 26, 328–335.
36 J. R. Galpin, L. G. M. Tielens, G. A. Velkdink, J. F. G. Vliegenthart
and J. Boldingh, FEBS Lett., 1976, 69, 179–182.
37 V. M. Darley-Usmar, A. Hersey and L. G. Garland, Biochem. Pharm.,
1989, 38, 1465–1469.
17 M. Katz and F. Saibil, J. Clin. Gastroenterol., 1990, 12, 203–206; N.
Sheikh, R. M. Philen and L. A. Love, Arch. Intern. Med., 1997, 157,
913–919; S. C. Sahu, D. I. Ruggles and M. W. O’Donnell, Food Chem.
Toxicol., 2006, 44, 1751–1757.
18 (a) D. A. Pratt, G. A. DiLabio, G. Brigati, G. F. Pedulli and L.
Valgimigli, J. Am. Chem. Soc., 2001, 123, 4625–4626; (b) L. Valgimigli,
G. Brigati, G. F. Pedulli, G. A. DiLabio, M. Mastragostino, C.
Arbizzani and D. A. Pratt, Chem. Eur. J., 2003, 9, 4997–5010; (c) M.
Wijtmans, D. A. Pratt, L. Valgimigli, G. A. DiLabio, G. F. Pedulli
5112 | Org. Biomol. Chem., 2009, 7, 5103–5112
This journal is
The Royal Society of Chemistry 2009
©